Moderna on Monday reiterated its expected COVID-19 vaccine sales of $6 billion to $8 billion for 2023 amid the uncertainty of vaccination rates in the US.
The biotechnology company said it anticipates being in the bottom half of the range if the US market for COVID-19 jabs registers 50 million administered doses in 2023, and projects to be within the top half for 100 million administered doses.
Moderna will provide an update after evaluating full vaccination trends through October.